Showed reduced efficacy compared to comparator arm (Il Sole 24 Ore Radiocor) - Bern, 04 Jul - Swiss pharmaceutical company Roche said it was halting the Phase II/III SKYSCRAPER-06 trial evaluating tiragolumab plus Tecentriq and chemotherapy as an initial treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer as it did not meet the primary endpoints of progression-free survival and overall survival.

The combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy compared to the comparator arm.

AAA-Sch

(RADIOCOR) 04-07-24 10:15:47 (0219) 5 NNNN